The data in the P3 MARQUEE NSCLC trial has still not matured for the EGFR mutant sub-group. What are they waiting for? With recent restructuring, cash runway has been extended another year (into 2017 now). Stop paying Pucci $750,000/y plus bonuses. Cut ARQL sr. management compensation by at least 10-20%